Multi-Faceted Role of Luteolin in Cancer Metastasis: EMT, Angiogenesis, ECM Degradation and Apoptosis.
Maria Teresa RocchettiFrancesco BellantiMariia ZadorozhnaDaniela FioccoDomenica MangieriPublished in: International journal of molecular sciences (2023)
Luteolin (3',4',5,7-tetrahydroxyflavone), a member of the flavonoid family derived from plants and fruits, shows a wide range of biomedical applications. In fact, due to its anti-inflammatory, antioxidant and immunomodulatory activities, Asian medicine has been using luteolin for centuries to treat several human diseases, including arthritis, rheumatism, hypertension, neurodegenerative disorders and various infections. Of note, luteolin displays many anti-cancer/anti-metastatic properties. Thus, the purpose of this review consists in highlighting the relevant mechanisms by which luteolin inhibits tumor progression in metastasis, i.e., affecting epithelial-mesenchymal transition (EMT), repressing angiogenesis and lysis of extracellular matrix (ECM), as well as inducing apoptosis.
Keyphrases
- extracellular matrix
- epithelial mesenchymal transition
- endothelial cells
- anti inflammatory
- oxidative stress
- transforming growth factor
- blood pressure
- endoplasmic reticulum stress
- cell death
- small cell lung cancer
- signaling pathway
- cell cycle arrest
- vascular endothelial growth factor
- rheumatoid arthritis
- papillary thyroid
- poor prognosis
- lymph node metastasis